IACT Health is proud to announce the success of a clinical trial in partnership with Sunovion Pharmaceuticals. Due to the success of IACT’s clinical trial, a new long-acting nebulizer inhaler, Lonhala Magnair, has been approved for long-term maintenance treatment in patients with COPD, including bronchitis and emphysema. This approval provides physicians and patients with the first nebulized LAMA as an additional therapeutic option for the management of COPD.

IACT Health has just become the latest network of clinical research sites to take advantage of Devana Solutions® IGNITE FOR SITES advanced central data analytics technology for clinical trial sites. The decision puts the 12-year old network of sites in good company as many of the industry leading sites and networks that have adopted Devana’s IGNITE can report not only their historical performance metrics but can also capture and deliver their site timing and performance metrics to Sponsors and CROs

The FDA agency is streamlining how it reviews and approves drugs, tests, and medical devices. “We are at an inflection point when it comes to the reductionist design process [of trials]” FDA’s Frank Weichold, MD, Ph.D. said. The agency is moving towards a more holistic approach and wants future trials to consider study design and timeline in regards to the objectives and more flexibility. Weichold envisions a world in which patients willingly and freely share comprehensive health data in a

Columbus Regional Research Institute and IACT Health are testing an investigational drug on Crohn’s disease to see if it can reduce the symptoms of flare-ups. If you are 18-75 yrs old and have not had previous luck with prescribed medications, and are currently having a flare-up, you may be eligible for the trial. IACT Health is a Columbus based regional clinical research site network uniquely staffed entirely by specialists. From locations throughout the Southeast, IACT Health conducts studies for the

A large percentage of cancer patient survivors are excluded from clinical trials if they develop cancer again according to researchers from UT Southwestern’s Simmons Cancer Center. “As the cancer survivor population continues to grow, understanding the nature and impact of a prior cancer is crucial to trial recruitment as well as to generalization of results,” said first author Dr. Caitlin Murphy, Assistant Professor of Clinical Sciences at UT Southwestern. Concerns about trial outcomes that don’t take into account the efficacy

The Discovery Channel is in the middle of a three-part documentary called First in Human, which is shining a spotlight on the National Institutes of Health’s (NIH) Building 10, home to countless clinical trials since it opened in the 1950s. If the first episode is any indication, tonight’s installment will be both suspenseful and educational, offering a highly detailed look into what patients experience when they volunteer to be human guinea pigs. The series comes at a time when clinical trial participants are

There are over 100 clinical trials available to the Columbus area through the Columbus Regional Research Institute (CRRI). Of that, half of these trials are committed to the study and treatment of cancer. That is why CRRI and IACT Health, and the John B. Amos Cancer Center are pleased to announce a strategic partnership in the field of oncology research. This new partnership will dramatically expand the scope of cancer research in the Southeast Region. “There is no doubt that

Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric antigen receptor (CAR) T-cell immunotherapy. The researchers also found that measuring genetic traces of cancer cells taken from bone marrow biopsies might be a better indicator of prognosis than the standard lymph node scan. The Journal of Clinical Oncology published the results online July 17 of the Phase 1/2 clinical trial,

Clinical research is featured in this month’s edition of Columbus and The Valley magazine. (Pages 21-24) http://www.digitalcolumbusandthevalley.com/Olive/ODN/ColumbusAndTheValley/default.aspx?href=CATV/2017/06/01